Inara Desidério | Hospital Israelita Albert Einstein (original) (raw)

Related Authors

Roberto  Esteves

Yaira Mathison

AGUSTIN ZERON

Kayhan  Bolelli

Edvaldo Soares

Edvaldo Soares

Universidade Estadual Paulista "Júlio de Mesquita Filho"

Om Prakash

Renata S. Sousa-Lima

Dr. Anika Niambi Al-Shura, BSc, MSOM, PhD

pinar cevik

Uploads

Papers by Inara Desidério

Research paper thumbnail of The role of biologics in eosinophilic esophagitis

Arquivos de Asmas Alergia e Imunologia, 2021

Eosinophilic esophagitis (EoE) is a chronic inflammation in the esophageal mucosa driven by an an... more Eosinophilic esophagitis (EoE) is a chronic inflammation in the esophageal mucosa driven by an antigen-mediated abnormal immune response with apparent increasing prevalence worldwide. Genetically predisposed individuals present with a dysfunctional esophageal barrier and an abnormal immune response mediated by Th2 and IgE against certain allergens. Consequently, esophageal lesions can cause dysmotility, fibrosis and loss of esophageal barrier function. Clinical manifestations are age-related and include symptoms of esophageal dysfunction. Diagnosis is established by specific histological features associated with the presence of at least 15 eosinophils per high-power field. Management of EoE includes control of allergic diseases with diet restrictions and/or pharmacological treatment with proton-pump inhibitors and corticosteroids, not completely effective and limited by possible side effects and impairment of quality of life. Although immunological mechanisms of EoE are still less clear than other allergic diseases, biologic trials indicate some promising perspectives for EoE management. The purpose of this review is to present the current evidence of biologic drugs as options for EoE treatment.

Research paper thumbnail of The role of biologics in eosinophilic esophagitis

Arquivos de Asmas Alergia e Imunologia, 2021

Eosinophilic esophagitis (EoE) is a chronic inflammation in the esophageal mucosa driven by an an... more Eosinophilic esophagitis (EoE) is a chronic inflammation in the esophageal mucosa driven by an antigen-mediated abnormal immune response with apparent increasing prevalence worldwide. Genetically predisposed individuals present with a dysfunctional esophageal barrier and an abnormal immune response mediated by Th2 and IgE against certain allergens. Consequently, esophageal lesions can cause dysmotility, fibrosis and loss of esophageal barrier function. Clinical manifestations are age-related and include symptoms of esophageal dysfunction. Diagnosis is established by specific histological features associated with the presence of at least 15 eosinophils per high-power field. Management of EoE includes control of allergic diseases with diet restrictions and/or pharmacological treatment with proton-pump inhibitors and corticosteroids, not completely effective and limited by possible side effects and impairment of quality of life. Although immunological mechanisms of EoE are still less clear than other allergic diseases, biologic trials indicate some promising perspectives for EoE management. The purpose of this review is to present the current evidence of biologic drugs as options for EoE treatment.

Log In